Canadian flagCanadian fulfilment · Free shipping $199+For laboratory research only
My account →Peptide Points →About Peptide Place →

Compound comparison

Semaglutide vs Tirzepatide vs Retatrutide

Published October 29, 2026 · Updated November 9, 2026

Editorial cover for Semaglutide vs Tirzepatide vs Retatrutide
Editorial illustration · read the original sources for evidence.

A clear comparison

Semaglutide targets GLP-1 receptors, tirzepatide targets GIP and GLP-1 receptors, and retatrutide targets GIP, GLP-1 and glucagon receptors. More targets alone do not establish a better result.

The differences at a glance

Reference facts and current product information are separate below. On a small screen, swipe within the table; keyboard users can focus it and scroll with the arrow keys.

Compare Semaglutide and Tirzepatide and Retatrutide
CompareSemaglutideTirzepatideRetatrutide
Reference · material classGLP-1 receptor agonistGIP / GLP-1 receptor agonistSingle peptide
Reference · identity and compositionSemaglutide; supplied form and specifications require matching documentation.Tirzepatide; supplied form and specifications require matching documentation.Retatrutide. Supplied form and exact specification require matching documentation.
Reference · research questionMetabolic researchMetabolic researchWeight management
Reference · evidence and limitationsClinical comparisons describe specific interventions and populations, not the current research-material lot.Two receptor targets distinguish this material from semaglutide. A mechanism does not by itself rank clinical outcomes or establish a current lot result.Human trial evidence relates to specified investigational formulations and trial populations. This catalogue vial is not the trial formulation, and a larger package size does not mean a better outcome.
Reference · source papersAronne et al. (2025): tirzepatide compared with semaglutide
Aronne et al. (2025): tirzepatide compared with semaglutide
Jastreboff et al. (2023): phase 2 retatrutide obesity trial
Product · current sizes and prices5 mg · Price unavailable
Out of stock
10 mg · $64.99
In stock
5 mg · $44.99
In stock
5 mg · $69.99
In stock
10 mg · $99.99
In stock
20 mg · $179.99
In stock
Product · current stockOut of stockIn stockIn stock
Product · supplied specificationConfirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specificationsConfirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specificationsConfirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specifications
Product · matching lot recordsNo matching published record. Check Lab ResultsNo matching published record. Check Lab ResultsNo matching published record. Check Lab Results
Product · information and availabilityProduct informationView available optionsView available options

Product figures come from the current WooCommerce listing in the store currency. Package milligrams are nominal material amounts, not doses. No report for another sample or lot is substituted for a matching record.

One, two and three receptor targets

These names often appear together in weight-loss and weight-management searches. Their receptor profiles provide a simple starting map: semaglutide has one of the three target types in this comparison, tirzepatide has two, and retatrutide has three. Receptor count describes mechanism. It is not a clinical score and does not tell you that one product is appropriate for an individual.

Which studies are actually comparable?

A direct comparison gives participants different treatments within the same study design. The 2025 tirzepatide versus semaglutide obesity trial is such a study. The cited 2023 retatrutide study is a separate phase 2 trial. Comparing percentage changes across those separate papers without accounting for populations, follow-up, protocols and endpoints would produce a misleading league table.

Weight, visceral fat and metabolism

Body weight is one endpoint. Changes in glucose regulation, fat distribution and other metabolic measurements are different endpoints. Check which outcome the paper actually measured, how many people completed follow-up and which adverse events were reported. A short answer can explain the receptor difference, while the full paper is needed to understand the result.

What is available in this catalogue?

Tirzepatide and Retatrutide are listed in the Peptide Place research catalogue. Semaglutide is included here for comparison. The vial strengths shown in the catalogue describe nominal material amounts. The studies cited below evaluated specific trial formulations and do not establish equivalence with catalogue materials.

Common questions

Is retatrutide just another name for tirzepatide?

No. They are distinct compounds with different receptor profiles.

Can all three be ranked from these papers?

The cited studies do not provide a three-way head-to-head comparison. Separate trial results need context.

Original sources

These papers support the specific mechanisms or study models discussed above. They do not test the current Peptide Place catalogue batches.

Continue exploring

Semaglutide 5 mg: current options and full overview →

Tirzepatide: current options and full overview →

Retatrutide: current options and full overview →

Compare other peptides →

Retatrutide vs Tirzepatide

The main mechanism distinction is three receptor targets versus two: retatrutide is associated with GIP, GLP-1 and glucagon receptor agonism; tirzepatide is associated with GIP and GLP-1 receptor agonism. That identifies a pharmacological difference. It does not, by itself, rank outcomes. Compare study populations, trial design, duration and measured endpoints before comparing results. Read the source evidence above rather than treating separate trial percentages as a direct head-to-head result.

Retatrutide vs Semaglutide

Semaglutide targets GLP-1 receptors; retatrutide is described through GIP, GLP-1 and glucagon receptor activity. The useful next question is which study and outcome you are comparing. Mechanism, clinical findings and a supplied product specification are different layers of information. For a pathway explanation, read GLP-1, GIP and glucagon receptors explained.

Tirzepatide vs Semaglutide

Tirzepatide is commonly described as a dual GIP/GLP-1 receptor agonist, while semaglutide is a GLP-1 receptor agonist. A fair evidence comparison keeps the population, comparator and endpoint visible. This page brings the related comparisons together so you can compare the same definitions and sources. A compound appearing here does not imply it is currently sold in the catalogue. Use the live Shop for availability.

Related reading: Retatrutide research profile

Explore this topic further

The Peptide Place Insider

Your first order.
15% better.
Get 15% off
your first order.

Your welcome code, orders and Peptide Points. One free account.

Join Insider emails and create your free Peptide Place account. Unsubscribe anytime. Adults 19+.

Privacy · Offer terms · Already joined? Sign in